His Holiness the 14th Dalai Lama of Tibet met with patients and leaders of Huntsman Cancer Institute (HCI) and the University of Utah during a brief visit to Huntsman Cancer Institute today, Tuesday, June 21. His visit coincides with his appearance later in the afternoon at the University’s Jon M. Huntsman Center where he will speak about compassion and universal responsibility.
Office of Public Affairs
2000 Circle of Hope,
Salt Lake City, UT 84112
In the United States, someone is diagnosed with a blood-related cancer every three minutes. For many of them, a blood or marrow transplant is the only hope for a cure. More than two-thirds of these patients, however, don’t have a matched marrow donor in the family. Donor registries offer them the best hope for finding a match.
Eye cancer took the life of author and neurologist Oliver Sacks last year, bringing attention to the rare and deadly disease. Scientists have tried to develop precision treatments against cancers like this one, but the mutations that cause them have proven difficult to block with drugs.
Melanoma is the most deadly of all skin cancers. If melanoma is found early, it is easier to treat. Researchers at the University of Utah and Texas Tech University have identified a new approach for finding suspicious moles that could be melanoma: mole crowdsourcing. Crowdsourcing refers to using crowds of people, often recruited online, to accomplish tasks. An individual performing a skin self-exam can miss about half of melanomas. But with mole crowdsourcing, one example showed if at least 19 out of 100 people think a mole is suspicious, then a doctor should examine it. Researchers are developing a cell phone application that will allow people to take a photo of a mole and have that image evaluated by other users. Learn more in The Scope Radio podcast about mole crowdsourcing, or about our Melanoma Program and the services it offers to diagnose and treat this disease.
With so much information about cancer that is readily available, those impacted by a cancer diagnosis often experience a feeling of information overload. The Cancer Learning Center (CLC) at HCI provides a welcoming environment where patients, families, and the general public can get answers to their questions about cancer. Trained health educators help visitors and callers navigate the potential for information overload and provide current, accurate information about treatment, side effects, and coping strategies. This resource is free for anyone with questions about cancer. Learn more about the G. Mitchell Morris Cancer Learning Center and how it began in our 2010 Annual Report, and other Education and Outreach programs at HCI.
Despite studies that claim people with cancer are less likely to develop Alzheimer’s disease—raising the possibility that what triggers cancer also prevents the neurodegenerative disorder—a new investigation finds a more somber explanation. Many cancer patients don’t live long enough to get Alzheimer’s. The research, led by investigators at Huntsman Cancer Institute at the University of Utah, was published in The Journals of Gerontology: Series B.
Actress Angelina Jolie-Pitt made headlines when she went public with a decision to have a preventative double mastectomy and later surgery to remove her ovaries as well. Jolie-Pitt made these decisions because test results revealed she has a genetic mutation that significantly raises her risk of breast and ovarian cancer. This drew important attention to understanding inherited cancer risk – part of ongoing genetic research at Huntsman Cancer Institute (HCI).
Teamwork is the focus of HCI’s tumor boards, monthly meetings where all the specialists involved in treating a given type of cancer share their expertise to come up with a treatment plan for a patient. This exchange means every patient receives the best care, aiming not only for survival but the highest quality of life possible. Dan HedlundTogether a team of doctors, social workers, and investigative researchers create a plan to treat an individual’s cancer with a combination of therapies. Learn how one patient, Dan Hedlund, is now cancer-free after undergoing treatment through HCI’s sarcoma multidisciplinary team.
Huntsman Cancer Institute’s CEO and director, Mary Beckerle, PhD, has been asked to join Vice President Joe Biden’s Moonshot Program Initiative as an invited member of a new Blue Ribbon Panel, tasked with advising the National Cancer Advisory Board (NCAB) on the scientific opportunities available to accelerate progress against cancer and evaluate potential new investments in cancer research.
No one plans on having a medical emergency, but if one happens, an advance directive outlines your plans and wishes for medical care. It tells your doctor and your family what decisions to make on your behalf, if you are unable to speak for yourself. An advance directive is also called a living will. Even if you’re young and healthy, you can prepare for unforeseeable events with an advance directive. The forms for an advance directive vary by state, but most follow the same basic format. Learn more about advance directives and Utah advance health care directive forms and instructions from the University of Utah’s Center on Aging.
There are limits to precision medicine – the genome-mapping wave permeating health care these days. And no one is more aware of the gap between technology and science than cancer doctors. A panel gathered at Huntsman Cancer Institute (HCI) March 23 warned about the boundaries, even the dangers, of relying too much on “big data” to treat patients with uniquely variable diseases.
Inheriting a mutation in the APC gene leads to a nearly 100% lifetime risk of colorectal cancer. While colon cancer can be kept at bay by removing the large intestine, these patients also have up to a 15% risk of getting cancer in the small intestine, which is the leading cause of cancer death in this patient group. A new study published in the Journal of the American Medical Association (JAMA), has identified the first prevention treatment for these patients, a two-drug combination that significantly reduces the number and size of precancerous polyps in the small intestine.
The Huntsman 140 is a fundraising road cycling event on Saturday, June 18 in Salt Lake City, Utah. All funds raised through this one-day event go to Huntsman Cancer Foundation (HCF) to support cancer research at Huntsman Cancer Institute (HCI). Each rider is encouraged to fundraise $500 to support cancer research at HCI. This ride is ideal for cyclists of all levels--from avid riders taking on the 140-mile challenge to newer pedalers enjoying the rolling 25-mile course. The variety of courses include 25-, 50-, 75-, and 140-mile routes.
Cancer of unknown primary is a rare disease (3-5% of individuals diagnosed with cancer are diagnosed with a cancer of unknown primary) in which cancer cells have spread in the body but the place the cancer began is unknown. There are a number of reasons why the primary cancer may not be found. The primary tumor may be too small to find, or the body’s immune system may have already destroyed it. It’s also possible that the primary tumor was removed during surgery for another condition and doctors didn’t know the cancer was there. Cancer has a language all its own and it’s that much harder if English is not your first language. That’s where Guadalupe Tovar, a health educator and patient navigator at Huntsman Cancer Institute (HCI), comes in. She helps Hispanic families navigate their cancer care.
Vice President Joe Biden already was thinking about ways to share “big data” across disciplines, hospital systems and state borders in his quest to defeat cancer. But a five-volume gift of his family’s genealogy from leaders of The Church of Jesus Christ of Latter-day Saints, a crash course in the Utah Population Database and a round table discussion with cancer researchers at Huntsman Cancer Institute (HCI) Friday clinched it.
(February 26, 2016) – Today Huntsman Cancer Institute (HCI) hosted Vice President Joe Biden as a part of the White House administration’s “moonshot” initiative to double the rate of progress toward curing cancer. During his visit, the vice president toured the facility, was given an inside look at the Utah Population Database and participated in a roundtable discussion comprised of Huntsman Cancer Foundation board chairman Jon Huntsman Jr., CEO and director of HCI Dr. Mary Beckerle and Senator Orrin Hatch. Local cancer survivors and physicians, researchers and experts in the field also participated in the roundtable.
Prostate cancer is the most common cancer among men. In fact, 1 in 8 men will be diagnosed with prostate cancer during their lifetimes. Many patients receive a diagnosis of prostate cancer and immediately begin to imagine difficult and time-consuming radiation treatments, but Huntsman Cancer Institute is pioneering new technology to help these patients and offering them renewed hope for the future.
Cancer usually begins in one location and then spreads, but in 3-5% of cancer patients, the tissue where a cancer began is unknown. In these individuals a cancer diagnosis is made because it has metastasized to other sites. Patients with these so-called “cancers of unknown primary,” or CUP, have a very poor prognosis, with a median survival of three months. A new study in the Journal of the American Medical Association (JAMA) Oncology finds that family members of CUP patients are at higher risk of developing CUP themselves, as well as cancers of the lung, pancreas, colon, and some cancers of the blood.
Aspirin has been shown to decrease the risk of colorectal cancer and possibly other cancers. However, the risk of side effects, including in some cases severe gastrointestinal bleeding, makes it necessary to better understand the mechanisms by which aspirin acts at low doses before recommending it more generally as a preventative, says Cornelia Ulrich, PhD, Senior Director of Population Sciences at Huntsman Cancer Institute in Salt Lake City.
The U.S. Food and Drug Administration announced October 27 that it has approved, for the first time, an oncolytic (cancer-killing) viral therapy in the U.S. The drug was approved for use against late stage melanoma, a deadly skin cancer that can be difficult to treat.
Our media relations representatives are here to help reporters Monday-Friday, 7:30 am-5 pm.
Public Affairs Manager
Public Relations Associate
After-hours calls: Reporters calling before or after business hours on an urgent matter can page the University of Utah Health on-call media relations representative at 801-581-7387 and press 1.